Why Is HAEMONETICS CORP MAS (HAE) Stock Up Today?

Haemonetics shares surged 13.38% to $115.32, driven by a significant update regarding its supply agreement with CSL Plasma. The company announced that CSL plans to roll out Haemonetics' devices by the end of 2027. This development followed a non-exclusive supply pact entered in August, which allows CSL to utilize NexSys PCS devices and purchase related disposables in the United States.

What Happened

Haemonetics filed an 8-K on October 8, 2026, disclosing the updated terms of its partnership with CSL. Under the agreement, CSL will deploy the company's plasma collection systems across its U.S. operations. The stock had been trading in a narrow range recently, declining 3.9% over the previous eight sessions to $101.71. The announcement triggered a sharp re-rating, with the stock opening at $116.00, a 14.0% gap above the prior close. Analysts responded quickly to the news, with BTIG raising its price target to $130 from $110. Citigroup upgraded the stock to Buy with a $123 target, while Raymond James maintained its Outperform rating and raised its target to $125.

What The Data Shows

The intraday session saw high volatility, with the stock hitting a high of $125.45 at 7:55 AM ET before settling to a low of $111.66 by 9:30 AM ET. The final price stood at $115.66. Volume was recorded at 0.2 million shares, which is 0.2 times the three-month daily average. The company currently has a market cap of $4.7 billion and a P/E ratio of 49.4. Revenue has grown 0.4% over the trailing twelve months, and the net margin stands at 7.1%. The stock's beta is 0.61. On the 52-week tape, the stock printed one fresh high and 26 fresh lows on October 7, 2026, indicating a period of significant volatility prior to this move. The 52-week range extends from $48.17 to $110.45.

What To Watch

Investors will monitor the execution of the CSL rollout timeline, which is targeted for completion by the end of 2027. The upcoming Q1 2027 earnings call will provide further insight into how this supply agreement impacts revenue projections and operational metrics.